AbbVie Sets Biosimilar Expectations As It Prepares To Take The Plunge On Humira

US Brand Erosion Expected To Be 37% In 2023; Amgen Adalimumab Pricing ‘Not A Surprise’

 
• By Dave Wallace
  
Rollercoaster steep drop
AbbVie is preparing for a sharp drop in Humira revenues • Source: Shutterstock

More from Biosimilars

More from Products